Keywords: merck, co, singulair, effective, pediatric, activity-induced, asthma
Merck & Co's Singulair effective in pediatric activity-induced asthma
Article | 11 May 2000
Merck & Co's anti-asthma agent Singulair (montelukast) has beenshown to be effective in children with activity-induced asthma. It offers significant protection ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
